Financial Outlook

Financial Outlook

OUTLOOK 2019

Lundbeck’s financial results for 2019 are expected to be driven by the continued strong growth of Abilify Maintena®, Brintellix®/ Trintellix®, Northera® and Rexulti® which partially can offset the continued erosion of mature products such as Onfi®.
 
Lundbeck’s total revenue is expected to reach between DKK 16.1 billion and 16.7 billion in 2019 and EBIT is expected to be in the range between DKK 4.2 billion and 4.6 billion. Lundbeck’s main currencies are the USD, CNY and CAD. The financial guidance is based on currency levels as per end-January 2019 and includes an expected hedging effect of a loss of DKK 150-200 million. The financial guidance is summarized below:
 

FINANCIAL GUIDANCE 2019

DKK  2018 actual 2019 guidance
Revenue 18,117m 16.1-16.7bn
EBIT 5,301m 4.2-4.6bn
Tax rate 26.1% 26-28%

 

 

Disclaimer

Forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations.Factors that may affect future results include interest rate and exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof and unexpected growth in expenses. Pursuant to section 107a of the Danish Financial statements Act, listed companies are under an obligation to consider whether they wish to disclose whether material agreements will be affected in the event of a change of control of the company. For reasons of competition, Lundbeck does not wish to disclose this.

Annual results

AR

Lundbeck has published the Annual Report 2018. To view the report please click below.

 

English

Cookie Policy